+

WO2003000182A3 - Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie - Google Patents

Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie Download PDF

Info

Publication number
WO2003000182A3
WO2003000182A3 PCT/US2002/019464 US0219464W WO03000182A3 WO 2003000182 A3 WO2003000182 A3 WO 2003000182A3 US 0219464 W US0219464 W US 0219464W WO 03000182 A3 WO03000182 A3 WO 03000182A3
Authority
WO
WIPO (PCT)
Prior art keywords
cachexia
ppar
prevention
treatment
alpha ligands
Prior art date
Application number
PCT/US2002/019464
Other languages
English (en)
Other versions
WO2003000182A2 (fr
Inventor
Samuel D Wright
Original Assignee
Merck & Co Inc
Samuel D Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Samuel D Wright filed Critical Merck & Co Inc
Priority to US10/482,233 priority Critical patent/US20040167107A1/en
Priority to AU2002316299A priority patent/AU2002316299A1/en
Publication of WO2003000182A2 publication Critical patent/WO2003000182A2/fr
Publication of WO2003000182A3 publication Critical patent/WO2003000182A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode destinée au traitement ou à la prévention de la cachexie chez un patient, consistant à administrer une dose efficace d'un agoniste du récepteur PPARα au patient pour traiter ou prévenir la cachexie. L'invention concerne également des thérapies combinées et des compositions pharmaceutiques destinées au traitement ou à la prévention de la cachexie.
PCT/US2002/019464 2001-06-22 2002-06-19 Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie WO2003000182A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/482,233 US20040167107A1 (en) 2002-06-19 2002-06-19 Ppar-alpha ligands for the treatment or prevention of cachexia
AU2002316299A AU2002316299A1 (en) 2001-06-22 2002-06-19 Ppar-alpha ligands for the treatment or prevention of cachexia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30027401P 2001-06-22 2001-06-22
US60/300,274 2001-06-22

Publications (2)

Publication Number Publication Date
WO2003000182A2 WO2003000182A2 (fr) 2003-01-03
WO2003000182A3 true WO2003000182A3 (fr) 2003-05-08

Family

ID=23158415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019464 WO2003000182A2 (fr) 2001-06-22 2002-06-19 Ligands du recepteur ppar alpha destines au traitement ou a la prevention de la cachexie

Country Status (2)

Country Link
AU (1) AU2002316299A1 (fr)
WO (1) WO2003000182A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1761779B1 (fr) 2004-08-13 2007-10-24 Indivumed GmbH Utilisation de transthyretine en tant que biomarqueur de l'adenome; procede de detection et systeme de test

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036579A1 (fr) * 1996-03-30 1997-10-09 Glaxo Group Limited Utilisation d'agonistes du recepteur alpha active par un proliferateur de peroxysome pour traiter l'obesite
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997036579A1 (fr) * 1996-03-30 1997-10-09 Glaxo Group Limited Utilisation d'agonistes du recepteur alpha active par un proliferateur de peroxysome pour traiter l'obesite
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production

Also Published As

Publication number Publication date
WO2003000182A2 (fr) 2003-01-03
AU2002316299A1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
WO2002085303A3 (fr) Composes de tetracycline substitues destines au traitement de la malaria
WO2002098370A3 (fr) Methodes d'administration/dosage d'antagonistes de cd2 pour la prevention et le traitement des maladies auto-immunes ou inflammatoires
WO2005009342A3 (fr) Methode de traitement ou de prevention de troubles dermatologiques a l'aide d'un seul inhibiteur de la cyclooxygenase-2 ou en combinaison avec un agent de traitement dermatologique, et compositions contenant ceux-ci
WO2002089794A8 (fr) Methode de traitement de la douleur neuropathique et preparation pharmaceutique associee
AU6147301A (en) Compositions and methods for the treatment of colorectal cancer
WO2003051313A3 (fr) Prevention et traitement des troubles lies au stress oxydatif a l'aide de glutathione et d'enzymes de detoxification de phase ii
WO2002005791A3 (fr) Therapie antitumorale combinee
WO2002056912A3 (fr) Methode de traitement du cancer
WO2004078113A3 (fr) Traitement et prevention de l'obesite au moyen d'inhibiteurs de cox-2 seul ou en combinaison avec des agents d'amaigrissement
WO2004038001A3 (fr) Composes tetracycline substituee servant au traitement du paludisme
WO2005023179A3 (fr) Methodes combinees de traitement du cancer
WO2001045641A8 (fr) Inhibiteurs d'agregation de plaquettes induite par thrombine
WO2004091540A3 (fr) Methodes de traitement de la douleur et compositions associees
WO2001068125A3 (fr) Methodes et compositions de traitement et de prevention de la dyserection
WO2005058233A3 (fr) Methodes de traitement d'une pancreatite aigue
WO2002039994A3 (fr) Methodes de traitement et de prevention des calculs urinaires
WO2004039325A3 (fr) Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation
WO2003092606A3 (fr) Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques
WO2004017917A3 (fr) Procede pour la prevention et/ou le traitement de l'atherosclerose
PL368971A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
MXPA04001398A (es) Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo.
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
WO2000001415A3 (fr) Utilisation d'inhibiteurs de la proteine kinase c epsilon dans le traitement de la douleur
WO2002064160A3 (fr) Compositions pharmaceutiques inhibant la proliferation vasculaire et leur methode d'utilisation
ATE310509T1 (de) Methode zur behandlung eines analgesiebedürftigen patienten

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10482233

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载